Watch · Quality 41/100
Simple research view
ABT · Abbott Laboratories
$93.24 latest stored close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$ABT
Abbott LaboratoriesAbbott Laboratories is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $162B.
Council read · 6 methods
Watch — evidence is building
0 buyable · 3 watch · 3 avoid. Review the observed passes and blockers before reading the chart.
Earnings-risk mode
Normal technical setup
Thursday, July 16, 2026
Time not confirmed
No sourced report session or clock time
Deterministic evidence
ABT+3.04%
AI interpretation (optional)
Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.
Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.ABT Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Setup Quality
D
0/7 signals
✗
Stage 4 · Declining
✗
Power Trend 1d
✗ RS New High
✗ Trend 1/8
✗
No Pattern
✗ CANSLIM 46.2 (D)
✗ Gatekeeper
Base #1 (A)
Technical Analysis Report Card
$ABT · $93.24 · as of 2026-06-25 · multi-factor read
53
/ 100
Trend · Daily / Weekly / Monthly
Daily
▲ Recovering / early uptrend
Weekly
▬ Sideways / consolidating
Monthly
▬ Sideways / consolidating
Moving Averages
50-day$89.27 ↑
100-day$98.96 ↓
200-day$112.80 ↓
Bearish (50 < 200)
RSI (14)
Reading61.3 · Bullish
Bullish momentum — comfortably in buyer territory.
MACD (12/26/9)
StateBullish
Histogram+0.477
Bullish — MACD above its signal line and above zero. Histogram expanding.
Bollinger Bands (20,2)
%B / Width103% · 8.7%
Riding the upper band — strong momentum, but stretched.
Volume · Buyer vs Seller
Up/Down vol0.68 · Neutral
Rel volume1.22×
Balanced — up/down volume is roughly even; no clear hand. Recent volume is expanding versus its baseline.
Support & Resistance
R · $103.84swing level
R · $113.76swing level
R · $116.82swing level
Price · $93.24now
S · $87.07swing level
S · $84.96swing level
S · $81.9752-week low
Fibonacci · Downtrend swing
23.6% ◄ price here$93.18
38.2%$100.11
50.0%$105.72
61.8%$111.32
78.6%$119.30
Retracement resistance zones measured from the recent swing high down to the low.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for ABT — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendBelow 200-day MA50/200 bearishRS 13 (laggard)
Want this read in a legend's voice?
💬 Ask a Legend about ABT
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
🟡 3 of 6 legends are Watching — building, not yet a confirmed buy.
Avoid
Minervini D
Trend-template read: fails Price > 200-day MA (MA150 not stored).
Passing evidence
1.5 Price > 50-day MAPrice $93.24 vs MA50 $89.27
2. Revenue growth ≥ 20% YoY+31.4% YoY
Failing evidence
1.1 Price > 200-day MA (MA150 not stored)Price $93.24, MA200 $112.80
1.4 50-day MA > 200-day MA (MA150 not stored)MA50 $89.27, MA200 $112.80
Avoid
O'Neil D
CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
A: Annual earnings & revenue qualityRev +31.4% | ROE 12.2%
S: Base tightness (ATR% ≤ 4.5%)ATR% 2.50%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-23.3% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 13
Avoid
Weinstein D
Stage-analysis read: declining (Stage 4) is not an advancing Stage 2.
Passing evidence
No passing evidence available.
Failing evidence
Stage 2 (Advancing phase) confirmedStage 4 (Declining)
Price above 30-week MA (200-day proxy)Price $93.24 vs MA200 $112.80
Watch
Livermore C
Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$93.24
Detected patternFlat Base
Failing evidence
Relative strengthRS 13
Volume vs average1.22x
Watch
Darvas C
Box-theory read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$93.24
Detected patternFlat Base
Failing evidence
Relative strengthRS 13
Volume vs average1.22x
Watch
Wyckoff C
Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$93.24
Detected patternFlat Base
Failing evidence
Relative strengthRS 13
Volume vs average1.22x
Breakout Health
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▲ Rising
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net -6
Fundamentals & leadership quality — Minervini SEPA criteria · 2/7 met
C
2/7 SEPA
Separate score from the 8-point Trend Template (1/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
-23%
Revenue growth ≥20% YoY
+31%
Gross margin ≥30%
56%
ROE ≥17%
12%
RS rating ≥80 (leadership)
13
Stage 2 uptrend (Weinstein)
Stage 4
Within 25% of 52W high
-32.8%
Method Playbook
📋 Trade it like Weinstein
EXACT LEVELS · PRO
Weinstein D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro levelPublished-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis (historical · 30d ago)
Flat Base
⚠ Not actionable yet
41.0
score
RS Score
13
Trend
1/8 ✗
CANSLIM
46.2* (D)
depth pct: 7.1
base days: 35
prior uptrend pct: 20.5
weekly close spread pct: 4.5
vol dried: ✓
validation reason: valid generic setup
multi tf reason: weekly trend template 0/8 — not confirmed (needs ≥4/8)
Why This Setup?
Flat Base
Flat Base: 35d base, depth 7.1%, prior uptrend 21%. Pivot $136.80. | Weak trend (1/8) | High-confidence pattern (85%) | Readiness 49/100 (early) | CANSLIM 46.2 (D) | ⚠ Not actionable yet
The Universal Edge Check
The panel is uneasy
Too many universals unmet — this leans closer to a guess than a trade.
0/7
universals met
- In a confirmed uptrend Trend 1/8 — no uptrend; don't bottom-fish
- Risk is defined No stop — undefined risk
- Asymmetric reward No target set
- Not chasing (in range) Pivot distance unknown
- Volume confirms 1.2× average — light
- Clear of earnings in -12 days — event risk
- A relative-strength leader RS 13 — laggard
Minervini Trend Template
1/8Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$93.24 vs SMA150 $106.95 / SMA200 $112.80
SMA 150 above SMA 200
SMA150 $106.95 vs SMA200 $112.80
SMA 200 trending up
Slope -4.25 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $89.27
Price above SMA 50
$93.24 vs SMA50 $89.27
30%+ above 52W low
+13.7% from $81.97
Within 25% of 52W high
-32.8% from $138.84
RS score above 70
RS 13
Fundamentals
52W Range
20%
Mkt Cap SEC
162.4B
EPS QoQ
-23%
Rev YoY
+31%
ROE
12%
Gross Margin
56%
D/E
0.25
EPS TTM
$3.72
P/E TTM
25.1x
Float
1.7B
Insider
No Buy
Company
Legend AI snapshot
Abbott Laboratories
$93.24latest close
$162.4Bmarket cap
13RS rank
41setup score
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
D
46.2* CANSLIM
* disqualified on C, M
C · Curr. EPS
20
A · Annual EPS
68
N · New Highs
40
S · Supply/Demand
100
L · Leader RS
13
I · Inst. Spons.
96
M · Market
0
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
0/8
W. RS
29
W. Support
$81.97
W. Resist
$129.46
Weekly Structure
Trend
Falling
Tight Weeks
1
Confirmation
Bearish
Get the full picture on ABT
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.
Start 7-Day Free Trial